The decision comes after the FTC's warnings to drugmakers over the misuse of Orange Book patent listings to wrongly extend patent monopolies on brand-name drugs, per a Reuters report.
Amphastar’s albuterol sulfate inhalation aerosol is for the treatment or prevention of bronchospasm in certain patients with reversible obstructive airway disease.